SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway

Biomed Res Int. 2022 Oct 6:2022:9235837. doi: 10.1155/2022/9235837. eCollection 2022.

Abstract

Castration-resistant prostate cancer (CRPC) is still challenging to treat. Dissatisfaction with androgen signal-targeted therapy forces people to look for other treatment strategies. Therefore, this study is aimed at exploring the role of SOX8/Notch signaling in CRPC. The upregulation of SOX8, Notch4, and Hes5 indicated a poor progression-free survival (PFS) in CRPC patients. The expression of these proteins was also upregulated in enzalutamide-resistant LNCaP cells (Enza-R). Moreover, knocking down SOX8 inhibited malignant biological behaviors and decreased the activation of Notch signaling in Enza-R cells. Importantly, knocking down SOX8 obviously reversed the enzalutamide resistance in Enza-R cells, while RO0429097 (a γ secretase inhibitor inactivates Notch signaling) exerted similar effects. At last, we found that both SOX8 knockdown and/or RO0429097 suppressed tumor growth and bone metastasis in vivo. Altogether, our study indicated that the SOX8/Notch signaling is involved in CRPC and that these enzymes are possible targets to develop novel treatment for CRPC.

MeSH terms

  • Androgens
  • Benzamides
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm / genetics
  • Gamma Secretase Inhibitors and Modulators
  • Humans
  • Male
  • Nitriles / pharmacology
  • Phenylthiohydantoin
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Prostatic Neoplasms, Castration-Resistant* / genetics
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism
  • SOXE Transcription Factors* / metabolism
  • Signal Transduction

Substances

  • Androgens
  • Benzamides
  • Gamma Secretase Inhibitors and Modulators
  • Nitriles
  • Receptors, Androgen
  • SOX8 protein, human
  • SOXE Transcription Factors
  • Phenylthiohydantoin
  • enzalutamide